HDAC9 and renal cell carcinoma: Notably, treatment with Depsipeptide, a HDAC inhibitor, reduced cell proliferation and induced apoptosis in dose- and time-dependent manners in RCC cell lines, while increasing H3K9 acetylation, p21(WAF/CIP1) expression and phosphorylation of Bcl2 [158].